Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Short term Debt: 2015-2024

Historic Short term Debt for Syndax Pharmaceuticals (SNDX) over the last 4 years, with Dec 2024 value amounting to $12.1 million.

  • Syndax Pharmaceuticals' Short term Debt was N/A to $12.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $12.1 million, marking a year-over-year change of. This contributed to the annual value of $12.1 million for FY2024, which is N/A change from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Short term Debt stood at $12.1 million for FY2024, which was up 6,379.14% from $187,000 recorded in FY2021.
  • Syndax Pharmaceuticals' 5-year Short term Debt high stood at $12.1 million for FY2024, and its period low was $187,000 during FY2021.
  • Moreover, its 1-year median value for Short term Debt was $12.1 million (2024), whereas its average is $12.1 million.
  • Data for Syndax Pharmaceuticals' Short term Debt shows a maximum YoY slumped of 91.82% (in 2021) over the last 5 years.
  • Syndax Pharmaceuticals' Short term Debt (Yearly) stood at $2.3 million in 2020, then slumped by 91.82% to $187,000 in 2021, then reached $12.1 million in 2024.